Meloxicam, a COX-2 inhibitor, ameliorates ischemia/reperfusion injury in non-heart-beating donor livers

European Surgical Research

Volumn 47, Issue 3, 2011, Pages 109-117

  Stoffels, B ^f   Yonezawa, K ^a   Yamamoto, Y ^b   Schafer N ^f   Overhaus, M ^f   Klinge, U ^c   Kalff, J C ^f   Minor, T ^e,f   Tolba, R H ^d  

^a KYOTO UNIVERSITY   (Japan)

^b AKITA UNIVERSITY   (Japan)

^c Department of Surgery ^*  (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e Surgical Research Division   (Germany)

^f UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

COX 2 inhibition; Ischemia reperfusion injury; Liver preservation; Transplantation; Warm ischemia

Indexed keywords

ALANINE AMINOTRANSFERASE; BILE ACID; CYCLOOXYGENASE 2; GLUTAMATE LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE; MALONALDEHYDE; MELOXICAM; MESSENGER RNA; THROMBOXANE B2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME RELEASE; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; LIVER ISCHEMIA; MALE; NON HEART BEATING DONOR; NONHUMAN; ORGAN DONOR; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR RESISTANCE;

ANIMALS; APOPTOSIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; LIVER; LIVER TRANSPLANTATION; MALE; ORGAN PRESERVATION; OXIDATIVE STRESS; RATS; RATS, WISTAR; REPERFUSION INJURY; RNA, MESSENGER; THIAZINES; THIAZOLES; TISSUE DONORS; VASCULAR RESISTANCE;

EID: 79960257849     PISSN: 0014312X     EISSN: 14219921     Source Type: Journal    
DOI: 10.1159/000329414     Document Type: Article

References (57)

1. Kootstra G, Kievit JK, Heineman E: The non heart-beating donor. Br Med Bull 1997; 53: 844-853. (Pubitemid 27500809)
2. Reddy S, Zilvetti M, Brockmann J, McLaren A, Friend P: Liver transplantation from nonheart-beating donors: current status and future prospects. Liver Transpl 2004; 10: 1223-1232. (Pubitemid 39406075)
3. Arnold RM, Youngner SJ: Time is of the essence: the pressing need for comprehensive non-heart-beating cadaveric donation policies. Transplant Proc 1995; 27: 2913-2917.
4. Kootstra G: The asystolic, or non-heartbeating, donor. Transplantation 1997; 63: 917-921. (Pubitemid 27173009)
5. Abt P, Crawford M, Desai N, Markmann J, Olthoff K, Shaked A: Liver transplantation from controlled non-heart-beating donors: an increased incidence of biliary complications. Transplantation 2003; 75: 1659-1663. (Pubitemid 36629146)
6. Abt PL, Desai NM, Crawford MD, Forman LM, Markmann JW, Olthoff KM, Markmann JF: Survival following liver transplantation from non-heart-beating donors. Ann Surg 2004; 239: 87-92. (Pubitemid 38176377)
7. Kohli V, Gao W, Camargo CA Jr, Clavien PA: Calpain is a mediator of preservationreperfusion injury in rat liver transplantation. Proc Natl Acad Sci USA 1997; 94: 9354-9359. (Pubitemid 27357833)
8. Kohli V, Selzner M, Madden JF, Bentley RC, Clavien PA: Endothelial cell and hepatocyte deaths occur by apoptosis after ischemia-reperfusion injury in the rat liver. Transplantation 1999; 67: 1099-1105. (Pubitemid 29205570)
9. Gao W, Bentley RC, Madden JF, Clavien PA: Apoptosis of sinusoidal endothelial cells is a critical mechanism of preservation injury in rat liver transplantation. Hepatology 1998; 27: 1652-1660. (Pubitemid 28264691)
10. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA: Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996; 97: 2672-2679. (Pubitemid 26187355)
11. Portanova JP, Zhang Y, Anderson GD, Hauser SD, Masferrer JL, Seibert K, Gregory SA, Isakson PC: Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 1996; 184: 883-891.
12. Vane JR: Prostaglandins as mediators of inflammation. Adv Prostaglandin Thromboxane Res 1976; 2: 791-801.
13. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T: Structure of the human cyclooxygenase-gene. Biochem J 1994; 302(Pt 3):723-727.
14. Liu SF, Newton R, Evans TW, Barnes PJ: Differential regulation of cyclo-oxygenase-1 and cyclo-oxygenase-2 gene expression by lipopolysaccharide treatment in vivo in the rat. Clin Sci (Lond) 1996; 90: 301-306.
15. Masferrer JL, Seibert K, Zweifel B, Needleman P: Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 1992; 89: 3917-3921.
16. Mitchell JA, Larkin S, Williams TJ: Cyclooxygenase-2: regulation and relevance in inflammation. Biochem Pharmacol 1995; 50: 1535-1542.
17. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA: Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994; 91: 2046-2050. (Pubitemid 24092039)
18. Otto JC, Smith WL: Prostaglandin endoperoxide synthases-1 and-2. J Lipid Mediat Cell Signal 1995; 12: 139-156.
19. Creminon C, Habib A, Maclouf J, Pradelles P, Grassi J, Frobert Y: Differential measurement of constitutive (COX-1) and inducible (COX-2) cyclooxygenase expression in human umbilical vein endothelial cells using specific immunometric enzyme immunoassays. Biochim Biophys Acta 1995; 1254: 341-348.
20. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, van de Putte LB, Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1073. (Pubitemid 28418937)
21. Ehrlich K, Plate S, Stroff T, Gretzer B, Respondek M, Peskar BM: Peptidergic and cholinergic neurons and mediators in peptoneinduced gastroprotection: role of cyclooxygenase-2. Am J Physiol 1998; 274(5 Pt 1): G955-G964.
22. FU JY, Masferrer JL, Seibert K, Raz A, Needleman P: The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737-16740.
23. Minghetti L, Nicolini A, Polazzi E, Creminon C, Maclouf J, Levi G: Inducible nitric oxide synthase expression in activated rat microglial cultures is downregulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia 1997; 19: 152-160. (Pubitemid 27094132)
24. Nogawa S, Forster C, Zhang F, Nagayama M, Ross ME, Iadecola C: Interaction between inducible nitric oxide synthase and cyclooxygenase-after cerebral ischemia. Proc Natl Acad Sci USA 1998; 95: 10966-10971.
25. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF: Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1998; 115: 297-306. (Pubitemid 28363422)
26. Wilborn J, DeWitt DL, Peters-Golden M: Expression and role of cyclooxygenase isoforms in alveolar and peritoneal macrophages. Am J Physiol 1995; 268(2 Pt 1):L294-L301.
27. Williams JA, Shacter E: Regulation of macrophage cytokine production by prostaglandin E2. Distinct roles of cyclooxygenase-1 and-2. J Biol Chem 1997; 272: 25693-25699. (Pubitemid 27438886)
28. Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Drozdowicz D, Stachura J, Pajdo R, Hahn EG: Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-in healing of ischemia-reperfusion-induced gastric lesions. Eur J Pharmacol 1999; 385: 47-61.
29. Nagayama M, Niwa K, Nagayama T, Ross ME, Iadecola C: The cyclooxygenase-2 inhibitor NS-398 ameliorates ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 1999; 19: 1213-1219. (Pubitemid 30176449)
30. Otani Y, Takeyoshi I, Yoshinari D, Matsumoto K, Morishita Y: Effects of the COX-2 inhibitor FK3311 on ischemia-reperfusion injury in the rat lung. J Invest Surg 2007; 20: 175-180. (Pubitemid 47050380)
31. Feitoza CQ, Goncalves GM, Semedo P, Cenedeze MA, Pinheiro HS, Beraldo FC, dos Santos OF, Teixeira VP, dos Reis MA, Mazzali M, Pacheco-Silva A, Camara NO: Inhibition of COX 1 and 2 prior to renal ischemia/reperfusion injury decreases the development of fibrosis. Mol Med 2008; 14: 724-730.
32. Sunose Y, Takeyoshi I, Ohwada S, Tsutsumi H, Iwazaki S, Kawata K, Kawashima Y, Tomizawa N, Matsumoto K, Morishita Y: The effect of cyclooxygenase-2 inhibitor FK3311 on ischemia-reperfusion injury in a canine total hepatic vascular exclusion model. J Am Coll Surg 2001; 192: 54-62. (Pubitemid 32064098)
33. Takeyoshi I, Sunose Y, Iwazaki S, Tsutsumi H, Aiba M, Kasahara M, Ohwada S, Matsumoto K, Morishita Y: The effect of a selective cyclooxygenase-2 inhibitor in extended liver resection with ischemia in dogs. J Surg Res 2001; 100: 25-31. (Pubitemid 32802699)
34. Oshima K, Yabata Y, Yoshinari D, Takeyoshi I: The effects of cyclooxygenase (COX)-2 inhibition on ischemia-reperfusion injury in liver transplantation. J Invest Surg 2009; 22: 239-245.
35. Montalvo-Javé EE, Ortega-Salgado JA, Castell A, Carrasco-Daza D, Jay D, Gleason R, Muñoz E, Montalvo-Arenas C, Hernández-Muñoz R, Piña E: Piroxicam and meloxicam ameliorate hepatic oxidative stress and protein carbonylation in Kupffer and sinusoidal endothelial cells promoted by ischemia-reperfusion injury. Transpl Intl 2011; 24: 489-500.
36. Ozturk H, Gezici A, Ozturk H: The effect of celecoxib, a selective COX-2 inhibitor, on liver ischemia/reperfusion-induced oxidative stress in rats. Hepatol Res 2006; 34: 76-83. (Pubitemid 43137555)
37. Ito Y, Katagiri H, Ishii K, Kakita A, Hayashi I, Majima M: Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion-induced hepatic microcirculatory dysfunction in mice. Eur Surg Res 2003; 35: 408-416. (Pubitemid 37034391)
38. Engelhardt G, Homma D, Schnitzler C: Meloxicam: a potent inhibitor of adjuvant arthritis in the Lewis rat. Inflamm Res 1995; 44: 548-555. (Pubitemid 26008751)
39. Engelhardt G, Bogel R, Schnitzler C, Utzmann R: Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem Pharmacol 1996; 51: 29-38.
40. Pairet M, van Ryn J, Schierok H, Mauz A, Trummlitz G, Engelhardt G: Differential inhibition of cyclooxygenases-1 and-2 by meloxicam and its 4f-isomer. Inflamm Res 1998; 47: 270-276. (Pubitemid 28325586)
41. Busch U, Schmid J, Heinzel G, Schmaus H, Baierl J, Huber C, Roth W: Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Dispos 1998; 26: 576-584. (Pubitemid 28498364)
42. Minor T, Yamaguchi T, Klauke H, Wingenfeld P, Michalk D, Isselhard W: Taurine reduces experimental liver injury after cold ischemic preservation and a period of rewarming prior to reperfusion. Adv Exp Med Biol 1996; 403: 157-161. (Pubitemid 26365195)
43. Minor T, Akbar S, Tolba R, Dombrowski F: Cold preservation of fatty liver grafts: prevention of functional and ultrastructural impairments by venous oxygen persufflation. J Hepatol 2000; 32: 105-111. (Pubitemid 30039454)
44. Minor T, Kotting M: Gaseous oxygen for hypothermic preservation of predamaged liver grafts: fuel to cellular homeostasis or radical tissue alteration? Cryobiology 2000; 40: 182-186. (Pubitemid 30314265)
45. Casavilla A, Ramirez C, Shapiro R, Nghiem D, Miracle K, Fung JJ, Starzl TE: Liver and kidney transplantation from non-heart beating donors: the Pittsburgh experience. Transplant Proc 1995; 27: 710-712.
46. Suarez F, Otero A, Solla M, Arnal F, Lorenzo MJ, Marini M, Vazquez-Iglesias JL, Gomez M: Biliary complications after liver transplantation from Maastricht category-2 nonheart-beating donors. Transplantation 2008; 85: 9-14.
47. Minor T, Hachenberg A, Tolba R, Pauleit D, Akbar S: Fibrinolytic preflush upon liver retrieval from non-heart beating donors to enhance postpreservation viability and energetic recovery upon reperfusion. Transplantation 2001; 71: 1792-1796. (Pubitemid 32622492)
48. Bowers BA, Branum GD, Rotolo FS, Watters CR, Meyers WC: Bile flow-an index of ischemic injury. J Surg Res 1987; 42: 565-569. (Pubitemid 17091906)
49. Clavien PA, Harvey PR, Strasberg SM: Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies. Transplantation 1992; 53: 957-978.
50. Marzi I, Walcher F, Menger M, Buhren V, Harbauer G, Trentz O: Microcirculatory disturbances and leucocyte adherence in transplanted livers after cold storage in Euro-Collins, UW and HTK solutions. Transpl Int 1991; 4: 45-50.
51. Menger MD, Lehr HA, Messmer K: Role of oxygen radicals in the microcirculatory manifestations of postischemic injury. Klin Wochenschr 1991; 69: 1050-1055.
52. Jaeschke H, Farhood A: Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. Am J Physiol 1991; 260(3 Pt 1):G355-G362.
53. Jaeschke H, Smith CW: Mechanisms of neutrophil-induced parenchymal cell injury. J Leukoc Biol 1997; 61: 647-653. (Pubitemid 27276056)
54. Harada N, Okajima K, Uchiba M, Kushimoto S, Isobe H: Antithrombin reduces ischemia/reperfusion-induced liver injury in rats by activation of cyclooxygenase-1. Thromb Haemost 2004; 92: 550-558. (Pubitemid 39248011)
55. Naka Y, Roy DK, Liao H, Chowdhury NC, Michler RE, Oz MC, Pinsky DJ: cAMP-mediated vascular protection in an orthotopic rat lung transplant model. Insights into the mechanism of action of prostaglandin E1 to improve lung preservation. Circ Res 1996; 79: 773-783. (Pubitemid 26317825)
56. Sunose Y, Takeyoshi I, Ohwada S, Tsutsumi H, Iwazaki S, Kawata K, Kawashima Y, Kasahara M, Matsumoto K, Morishita Y: Selective cyclooxygenase-2 inhibitor ameliorates warm ischemia-reperfusion injury of the canine liver. Transplant Proc 2001; 33: 862. (Pubitemid 32237660)
57. Takeyoshi I, Sunose Y, Iwazaki S, Tsutsumi H, Aiba M, Tomizawa N, Kawashima Y, Kasahara M, Kawate S, Ogawa T, Ohwada S, Matsumoto K, Morishita Y: The effect of cyclooxygenase 2. inhibitor (FK3311) on ischemia-reperfusion injury with hepatectomy in dogs. Transplant Proc 2000; 32: 2322-2323.